Gross Profit Comparison: AbbVie Inc. and Takeda Pharmaceutical Company Limited Trends

Pharma Giants' Profit Trends: AbbVie vs. Takeda

__timestampAbbVie Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014155340000001256834000000
Thursday, January 1, 2015183590000001271973000000
Friday, January 1, 2016198050000001173296000000
Sunday, January 1, 2017211760000001274610000000
Monday, January 1, 2018250350000001437534000000
Tuesday, January 1, 2019258270000002201424000000
Wednesday, January 1, 2020304170000002203504000000
Friday, January 1, 2021387510000002462160000000
Saturday, January 1, 2022406400000002783406000000
Sunday, January 1, 2023339030000002832257000000
Monday, January 1, 2024394300000002832257000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: AbbVie Inc. vs. Takeda Pharmaceutical

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and innovation capacity. From 2014 to 2023, AbbVie Inc. and Takeda Pharmaceutical Company Limited have shown distinct trends in their gross profits. AbbVie, a leader in immunology and oncology, saw its gross profit grow by approximately 118% from 2014 to 2022, peaking in 2022 before a slight dip in 2023. Meanwhile, Takeda, a global powerhouse in rare diseases and gastroenterology, maintained a steady upward trajectory, with a 125% increase over the same period, reaching its highest in 2023. This comparison highlights the resilience and strategic growth of these companies, despite the challenges posed by global economic shifts and healthcare demands. Missing data for AbbVie in 2024 suggests a need for further analysis to understand future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025